

The International Charitable Foundation “Alliance for Public Health” (formerly known as the International Charitable Foundation “International HIV/AIDS Alliance in Ukraine” until November 2015) (hereinafter – Alliance) is a leading non-governmental professional organization making a significant impact on the epidemics of HIV/AIDS, tuberculosis, viral hepatitis and other socially dangerous diseases in Ukraine. In cooperation with state partners and civil society organizations, it provides financial and technical support to programs, covering over 250,000 representatives of most vulnerable populations: the highest such coverage indicator in Europe.
In 2018 Alliance received international accreditation from the Frontline AIDS (UK). Alliance has received the highest professional accreditation to confirm that it complies with nine principles in the areas “Governance and Sustainability”, “Organisational Management” and “HIV Programming” based on 38 standards. Currently it is the only organization in Eastern Europe and Central Asia with such accreditation.
Since the beginning of the full-scale invasion, as part of the Alliance’s HIV prevention programs, 108,671 HCV rapid tests have been held, which is almost twice as much as in 2021 (most of them among representatives of HIV vulnerable groups, in particular drug users), of which 37% turned out to be positive! Out of 12,600 viral hepatitis B tests, 2.5% were positive. Starting from February 24, 2022, the Alliance has offered access to HCV diagnosis and treatment to more than 3,300 people living with HIV and tuberculosis and their partners, i.e. to one in every six of those covered with treatment at the national level. Adherence to treatment remained extremely high – 98%, due to that every patient was accompanied by non-governmental organization workers during their treatment and 12 weeks after. The Alliance does everything possible to ensure continuity of treatment for patients who are internally displaced within Ukraine or refugees abroad.
The most important role in organization of HCV testing, diagnosis, and treatment is performed by our partner nongovernmental organizations. They are the ones who test, provide information and social support to representatives of key populations, refer for HCV diagnosis and treatment, conduct counselling, accompany treatment, form adherence to it, carry out extensive educational work, etc. All in all, since 2015, as part of the Alliance’s HCV treatment program, more than 12,000 people from among the most vulnerable groups have gained access to HCV diagnosis and treatment. These are people living with HIV, drug users, men having sex with men, and sex workers. 99% of them are drug users who have HIV/HCV or TB/HCV co-infection, as well as their partners.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close